Edwards Lifesciences (EW) stock faces a downgrade at Wolfe due to concerns over its TAVR market prospects. Read more here.

Wedgewood Partners, an investment management company, released its fourth-quarter 2024 investor letter. A copy of the letter ...

Wolfe Research downgraded Edwards Lifesciences (EW) to Underperform from Peer Perform with a $60 price target The firm says its core ...

In a report released yesterday, Lee Hambright from Bernstein maintained a Hold rating on Edwards Lifesciences (EW – Research Report). The ...

Capital Investment Advisors LLC lowered its stake in shares of Edwards Lifesciences Co. (NYSE:EW – Free Report) by 2.4% during the fourth quarter, according to its most recent disclosure with the ...

Zacks Research raised their FY2024 earnings per share (EPS) estimates for Edwards Lifesciences in a research note issued on ...

Daniel J. Lippis, the Corporate Vice President for JAPAC at Edwards Lifesciences Corp (NYSE:EW), has disclosed recent stock ...

Wolfe Research adjusted its perspective on Edwards Lifesciences (NYSE:EW) shares, downgrading its rating from Peerperform to ...

Edwards Lifesciences Corp. engages in the patient ... Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart and Critical Care. The Transcatheter ...

Cardiac device innovations made waves in 2024, with regulatory approvals, clinical breakthroughs, and product launches ...

The US Supreme Court rejected a case asking the justices to interpret a patent-infringement safe-harbor provision in a ...

North America to Lead Revenue While Asia Pacific Emerges as the Fastest-Growing Region, Driven by Rising Cardiovascular Cases ...